Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The companys principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimers disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntingtons disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
February 28, 2022
RegMed Investors’ (RMi) closing bell: despite starting with a sell-off, the cell and gene therapy reaped a bare upside as the oversold lost and gained momentum
February 25, 2022
RegMed Investors’ (RMi) closing bell: share pricing risk decline from a headline drive market to close sector positive
February 25, 2022
RegMed Investors’ (RMi) pre-open: turning or burning - the sector correction beyond the invasion of Ukraine
February 24, 2022
RegMed Investors’ (RMi) closing bell: a lot of buys on first day of a disclosed Ukraine attack
February 24, 2022
RegMed Investors’ (RMi) pre-open: the invasion/attack has begun shaking global markets
February 23, 2022
RegMed Investors’ (RMi) closing bell: what happened, blood from the past and on-going sessions drowns sentiment
February 23, 2022
RegMed Investors’ (RMi) pre-open: overcoming resistance to instill a little lost confidence
February 22, 2022
RegMed Investors’ (RMi) closing bell: stuck in the penalty box
February 22, 2022
RegMed Investors’ (RMi) pre-open: rolling in chaos and uncertainty
February 18, 2022
RegMed Investors’ (RMi) closing bell: what has changed, an escalation of fears
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.